NYSEARCA:ARMP - NYSE Arca - US04216R1023 - Common Stock - Currency: USD
Armata Pharmaceuticals stock surges 72% in a month following superior efficacy results from a phase Ib/IIa study of AP-SA02 for treating an infectious disease.
Armata Pharmaceuticals (ARMP) delivered earnings and revenue surprises of 47.37% and 64.42%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: DTIL
ARMP, COLM and EFSI have been added to the Zacks Rank #5 (Strong Sell) List on May 8, 2025.
CCS, ARMP and CABO have been added to the Zacks Rank #5 (Strong Sell) List on April 28, 2025.
ADC Therapeutics (ADCT) delivered earnings and revenue surprises of 5.26% and 26.94%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: ADCT
Sangamo (SGMO) delivered earnings and revenue surprises of -27.27% and 29.77%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: SGMO
ARMP stock results show that Armata Pharmaceuticals beat analyst estimates for earnings per share the second quarter of 2024.
Discover three high-growth stock picks set for unprecedented surges in the metals, marine transportation, and pharmaceutical industries.
ARMP stock results show that Armata Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
ARMP stock results show that Armata Pharmaceuticals missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023.
Biotechnology company focused on pathogen‐specific bacteriophage therapeutics for antibiotic‐resistant and difficult‐to‐treat bacterial infections, Armata Pharmaceuticals (ARMP) enters...
Mentions: INVA
It's time to start the day with a breakdown of all the biggest pre-market stock movers worth reading about on Thursday!
Armata Pharmaceuticals (ARMP) said its inhaled bacterial infection drug for lung disorder was well-tolerated with a treatment emergent adverse event ((TEAE)) profile similar to placebo...